Brokers Set Expectations for Genomic Health, Inc.’s Q1 2018 Earnings (GHDX)

Genomic Health, Inc. (NASDAQ:GHDX) – Investment analysts at William Blair issued their Q1 2018 EPS estimates for shares of Genomic Health in a report issued on Monday. William Blair analyst A. Murphy anticipates that the medical research company will post earnings of $0.07 per share for the quarter. William Blair also issued estimates for Genomic Health’s Q2 2018 earnings at $0.02 EPS, Q3 2018 earnings at $0.07 EPS and Q4 2018 earnings at $0.13 EPS.

GHDX has been the subject of several other reports. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. ValuEngine downgraded Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Canaccord Genuity reissued a “buy” rating and set a $35.00 price target on shares of Genomic Health in a research report on Wednesday, September 27th. Jefferies Group LLC reissued a “hold” rating and set a $33.00 price target on shares of Genomic Health in a research report on Thursday, September 14th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $31.00 price target on shares of Genomic Health in a research report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $32.00.

WARNING: “Brokers Set Expectations for Genomic Health, Inc.’s Q1 2018 Earnings (GHDX)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/11/14/brokers-set-expectations-for-genomic-health-inc-s-q1-2018-earnings-ghdx.html.

Genomic Health (NASDAQ:GHDX) opened at $28.59 on Tuesday. Genomic Health has a one year low of $26.37 and a one year high of $34.02.

Several large investors have recently made changes to their positions in the company. Wetherby Asset Management Inc. grew its position in shares of Genomic Health by 3.7% in the second quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 317 shares during the period. Dubuque Bank & Trust Co. grew its position in shares of Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 379 shares during the period. Parametric Portfolio Associates LLC grew its position in shares of Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after purchasing an additional 441 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Genomic Health by 3.4% in the second quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after purchasing an additional 520 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Genomic Health by 11.4% in the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after purchasing an additional 710 shares during the period. 89.13% of the stock is owned by institutional investors and hedge funds.

In other news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $31.47, for a total value of $157,350.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Insiders have sold 21,379 shares of company stock valued at $676,131 in the last three months. 46.20% of the stock is currently owned by company insiders.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply